Background and Purpose: Clinical and experimental studies suggest that platelets have a major role in the pathogenesis of cerebral ischemia. However, ex vivo both platelet aggregation studies and measurements of platelet-derived products in patients with cerebral ischemia have shown inconsistent results. The present study was designed to resolve this inconsistency.
Since thromboembolism from extracranial arteries is widely regarded as one of the most common causes of transient ischemic attacks (TIAs) and ischemic strokes, platelet function in these conditions has received increasing attention in the past years. A few older studies have reported platelet hyperaggregability,'-5 particularly in young stroke victims,1 but the validity of these in vitro studies has been challenged. 6 Others have studied in vivo platelet activation by measuring blood levels of a platelet-specific protein, f,-thromboglobulin, which is secreted from a-granules of activated platelets. 7 13 Some have found elevated levels of f-thromboglobulin in all types of transient or permanent cerebral ischemia or exclusively in some subtypes of stroke.13 A major drawback of many of these studies is that the measurements were not confined to the acute phase after the ischemic event but were performed up to 7 months later.12 Furthermore, ,3-thromboglobulin levels varied widely among these studies and showed a considerable overlap with those of control patients. These inconsistent results may be explained, at least in part, by ex vivo platelet activation during and after blood sampling; this artifact is a major disadvantage of testing platelet activation in peripheral blood.
To investigate the actual rate of thromboxane biosynthesis in vivo, we have studied the urinary excretion of a major enzymatic metabolite of thromboxane B2, 11- dehydro-thromboxane B2, in patients with acute cerebral ischemia and in appropriate control patients. Thromboxane A2 represents an amplification mechanism of platelet activation and aggregation by virtue of its being synthesized and released in response to a variety of agonists (e.g., collagen, ADP, and thrombin) and in turn inducing platelet aggregation. Evidence for enhanced thromboxane biosynthesis, as reflected by increased urinary excretion of thromboxane metabo-lites, has been reported in patients with unstable angina and acute myocardial infarction.14-16 In the present study, we sought to determine whether the formation of this potent platelet agonist is altered in vivo, in association with acute cerebral ischemia.
Subjects and Methods Study Patients
Between June 1987 and November 1990 a total of 51 consecutive patients with acute cerebral ischemia were prospectively studied. Fourteen patients (11 
Exclusions
Patients were excluded if they had been taking aspirin or other nonsteroidal anti-inflammatory drugs during the preceding 10 days. All other drugs were continued during the study period. Also excluded were patients requiring invasive investigations (particularly angiography) within the next 48 hours, patients with possible vasculitis (erythrocyte sedimentation rate >40 mm in the first hour), renal disease (creatinine >150 ,mol/l), or unstable angina pectoris (recent onset of class III-IV chest pain according to the Canadian Heart Association, in the absence of an increase in the muscle and/or brain fraction of plasma creatinine kinase).
Urine was collected during the night as soon as possible after admission to hospital in all patients. The median time between neurological symptoms and the first urine collection was 24 hours (range, from 2 hours to 8 days). In the first 25 of the patients with cerebral ischemia and in the first 10 control patients, urine was sampled again 24 hours later. The volume of each urine sample was recorded, and the creatinine concentration was measured. The samples were frozen immediately after voiding and stored at -20°C until extraction. In 11 unselected and consecutive stroke patients, additional overnight urine samples were collected on the third, fifth, and seventh day of treatment with 50 mg aspirin per day.
Immunoreactive il-dehydro-thromboxane B2 was extracted from 20-ml aliquots of each coded urine sample (the pH was adjusted to 4.0-4. we performed a logistic regression analysis. All numerical data are expressed as mean±+1 SD. A level of p<0.05 (two-sided testing) was considered statistically significant.
Results
The individual values of ll-dehydro-thromboxane B2 in all patients and controls are depicted in Figure 1 . These values ranged between 39 and 478 (median, 127) pmol/mmol creatinine in TIA patients and between 23 and 5,916 (median, 264) pmol/mmol creatinine in stroke patients. In four of the 14 TIA patients (29%; 95% confidence interval, 8-58%;p=0.18) and in 19 of the 37 stroke patients (51%; 95% confidence interval, 34-68%;p=0.004), the excretion rate exceeded 2 SD of the mean value of the control patients with nonvascular disorders (119±66 pmol/mmol creatinine). To account for minor differences in baseline data between the study and control patients, none of which reached statistical significance, we performed a logistic regression analysis. This showed that the difference in thromboxane production was independent of age and sex, vascular risk factors (in particular, diabetes), and the results of blood tests. Of all blood tests, only the platelet count moderately correlated with the li-dehydro-thromboxane B2 excretion rate (n=79, r=0.38,p=0.01). The mean platelet count did not differ significantly between the four patient groups. No correlation was found between the level of metabolite excretion and the time interval between the onset of neurological symptoms and the collection of urine in patients with cerebral ischemia. The episodic nature of changes in metabolite excretion was supported by repeated measurements performed on 2 consecutive days in the first 25 patients with cerebral ischemia (eight with TIA and 17 with stroke). Of these 25 patients, two TIA patients and six stroke patients had increased excretion rates on the first day; however, one TIA patient and two stroke patients had normal levels on the second occasion. The mean excretion rate in all patients with cerebral ischemia fell from 275 +225 pmol/mmol creatinine on day 1 to 160±132 pmol/mmol creatinine (p=0.08). In 10 control patients in whom urine was sampled twice, the mean excretion rate was within the same range on both occasions (63+21 pmol/ mmol creatinine the first time and 65+27 pmol/mmol creatinine the second time).
The rate of urinary excretion of il-dehydro-thromboxane B2 was not related to the nature, the duration, or the severity of clinical symptoms. In particular, an increased level was equally frequent in patients with and without headache during the attack. In stroke patients, metabolite excretion was not related to the type (cortical or "lacunar") or site (carotid versus vertebrobasilar territory) of cerebral infarction (Table 1 ).
In patients with atypical attacks, il-dehydro-thromboxane B2 averaged 99±40 pmol/mmol creatinine. In one of the eight patients with atypical attacks, the metabolite excretion was abnormally elevated ( Figure  1 ). This patient had been admitted with repeated dizzy spells, which were on one occasion followed by nonrotatory dizziness, nausea, and brief unconsciousness. Two days after admission this patient was found to have signs of myocardial ischemia on the ECG during a further attack.
To investigate whether the enhanced biosynthesis of thromboxane in patients with cerebral ischemia was of platelet or nonplatelet origin, we studied the short-term effects of a platelet-selective regimen of aspirin therapy (50 mg per day for 7 days) on metabolite excretion in 11 consecutive stroke patients. Before aspirin treatment, 11-dehydro-thromboxane B2 excretion averaged 889+±734 pmol/mmol creatinine. After 3 days of aspirin administration, metabolite excretion was significantly (p=0.002) reduced to 234±+224 pmol/mmol creatinine, and on the fifth and seventh days these values were further reduced to 164±78 and 129±63 pmol/mmol creatinine, respectively (Figure 2 ). This represented an average reduction of 85% in thromboxane biosynthesis in comparison with pretreatment measurements. This finding is consistent with the cumulative acetylation of platelet prostaglandin G/H synthase20 and inhibition of thromboxane production21 by low-dose aspirin, as previously found in healthy subjects. the present study, given the 45 -minute half-life of 11-dehydro-thromboxane B2 in the human circulation. 24 In contrast, enhanced thromboxane biosynthesis was a relatively more frequent finding in patients with an ischemic stroke. The fact that half of these patients had perfectly normal values of li-dehydro-thromboxane B2 excretion within the first week after the onset of symptoms suggests that platelet activation is of episodic nature also in patients with stroke. This suggestion is reinforced by the finding of markedly elevated metabolite excretion beyond 24 hours after the event in some patients, which would not be expected from the half-life of this metabolite if thromboxane-dependent platelet activation occurred as a single episode, at the time of the stroke. Together, our findings indicate that platelet activation resulting in thromboxane biosynthesis does not occur in all TIA or stroke patients, a finding consistent with the limited effect of antiplatelet therapy, which prevents only about one third of all strokes. 22 In patients with ischemic stroke, the excretion rate of 11-dehydro-thromboxane B2 was not related to the type (cortical or lacunar) or site (carotid versus vertebrobasilar) of cerebral infarction. This finding is at variance with the widely supported notion that the majority of lacunar infarcts are caused by local fibrinoid lipohyalinosis and subsequent occlusion of small perforating cerebral vessels and not by thromboembolism. 25 It is also at odds with the lower ,3-thromboglobulin levels in patients with lacunar infarcts, reported in a previous study. 13 In contrast, small deep infarcts may well have a more diverse pathogenesis than previously recognized. 26 Our finding that 60% of patients with a lacunar infarct have enhanced thromboxane biosynthesis suggests that aspirin may be a rational mode of secondary prevention in these patients as well.
An additional objective of our study was to investigate thromboxane biosynthesis in patients with atypical attacks that are not considered TIAs according to internationally accepted criteria.27 Many of these attacks represent global rather than focal cerebral ischemia and are therefore probably caused by hemodynamic changes, for instance, attacks secondary to cardiac arrhythmia rather than thromboembolism. In one of the eight patients in our study with such atypical symptoms, thromboxane metabolite excretion exceeded the upper limit of the control patients. This patient later showed ECG evidence of myocardial ischemia during an attack. This is consistent with a recent finding that patients with atypical attacks may be threatened by cardiac rather than cerebral events. 28 Finally, our finding that a daily dose of 50 mg aspirin can profoundly suppress enhanced thromboxane biosynthesis after acute cerebral ischemia should be viewed in the context of the apparent lack of a dose dependence in its prevention of strokes and myocardial infarction at 75-1,500 mg per day.22'29 This biochemical finding is consistent with the clinical observation recently made in the Dutch TIA trial that aspirin at 30 mg per day is at least as effective as 300 mg per day in reducing the risk of major vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death) in patients with TIA or minor stroke. 30 We conclude that 1) episodes of enhanced thromboxane biosynthesis are detected infrequently in patients with a transient ischemic attack, 2) aspirin-suppressible episodes of increased thromboxane formation can be detected during the early phase of acute ischemic stroke, and 3) this finding may provide a rationale for testing the efficacy and safety of this drug in this setting.
